TY - JOUR T1 - Effectiveness and Safety of Amphotericin B Deoxycholate, Amphotericin B Colloidal Dispersion, and Liposomal Amphotericin B as Third-Line Treatments for Cutaneous and Mucocutaneous Leishmaniasis: A Retrospective Study. AU - Rodríguez Galvis,María Claudia, AU - Pérez Franco,Jairo Enrique, AU - Casas Vargas,Mirian Yolanda, AU - Ordoñez Rubiano,María Fernanda, PY - 2019/12/11/pubmed PY - 2020/5/16/medline PY - 2019/12/11/entrez SP - 274 EP - 279 JF - The American journal of tropical medicine and hygiene JO - Am J Trop Med Hyg VL - 102 IS - 2 N2 - Cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL) are endemic diseases in America, especially in some countries such as Colombia. Among the therapeutic options is amphotericin B (AB). Nevertheless, its lipid-associated formulations have better safety profiles and effectiveness in other diseases, so far with no comparative studies in CL or MCL. We conducted a retrospective descriptive study describing the effectiveness and adverse effects of AB deoxycholate (ABD), AB colloidal dispersion (ABCD), and liposomal AB (LAB) as third-line treatments for CL and MCL. The effectiveness of LAB (88.5%) was greater than those of ABCD (66.6%) and ABD (80.8%). There were also fewer adverse effects in the LAB group (46.2%) than in the ABD (96.1%) and ABCD (80.9%) groups. LAB is an alternative for the treatment of CL and MCL in patients with therapeutic failure to first- and second-line drugs; findings suggest it might be less toxic and more effective than ABD and ABCD. SN - 1476-1645 UR - https://www.unboundmedicine.com/medline/citation/31820708/Effectiveness_and_Safety_of_Amphotericin_B_Deoxycholate_Amphotericin_B_Colloidal_Dispersion_and_Liposomal_Amphotericin_B_as_Third_Line_Treatments_for_Cutaneous_and_Mucocutaneous_Leishmaniasis:_A_Retrospective_Study_ L2 - https://ajtmh.org/doi/10.4269/ajtmh.18-0514 DB - PRIME DP - Unbound Medicine ER -